L'intérêt à découvert pour Pasithea Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Pasithea Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Pasithea Therapeutics (NASDAQ:KTTA) Stock, Rapport sur les intérêts à découvert

Pasithea Therapeutics

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. - Common Stock

Pasithea Therapeutics Corp

Wall Street analysts rerated ON Semiconductor Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) after the company reported upbeat quarterly results on Monday.
The company reported a <a target="_blank" href="https://www.benzinga.com/news/earnings/25/05/45196247/on-semiconductor-q1-earnings-beat-estimates-ceo-optimistic-on-design-wins-despite-margin-decline" rel="noreferrer noopener">quarterly&nbsp;revenue decline</a> of 22.4% to $1.45 billion, topping the&nbsp;analyst&nbsp;consensus estimate of $1.40 billion. The adjusted EPS of $0.55 beat the&nbsp;analyst consensus estimate&nbsp;of $0.51.
ON Semiconductor expects second-quarter adjusted revenue of $1.40 billion-$1.45 billion, compared to the analyst consensus estimate of $1.42 billion. The company expects quarterly adjusted EPS of 48 cents to 58 cents. That&#8217;s above the analyst consensus estimate of 45 cents and an adjusted gross margin of 36.5%-38.5%.
<ul>
<li>Benchmark analyst David Williams maintained ON Semiconductor with a Buy and lowered the <a target="_blank" href="https://www.benzinga.com/quote/ON/analyst-ratings" rel="noreferrer noopener">price target from&nbsp;$60&nbsp;to&nbsp;$50</a>.</li>
<li>Rosenblatt analyst Kevin Cassidy reiterated ON Semiconductor with a Neutral and a $42&nbsp;price target.</li>
<li>Needham analyst Quinn Bolton maintained ON Semiconductor with a Buy and lowered the price target from&nbsp;$57&nbsp;to&nbsp;$50.</li>
</ul>
Also Read: <a href="https://www.benzinga.com/news/earnings/25/05/45196247/on-semiconductor-q1-earnings-beat-estimates-ceo-optimistic-on-design-wins-despite-margin-decline" target="_blank" rel="noreferrer noopener">ON Semiconductor Q1 Earnings Beat Estimates, CEO Optimistic On Design Wins Despite Margin Decline</a>
Benchmark:  Revenue was about $46 million ahead of the prior guidance. Lower operating expenditures drove a 5 cent earnings upside. Williams remains encouraged by the flattish guide. End markets have mostly stabilized following six consecutive quarters in decline, where sales have fallen 34% from the second-quarter 2023 peak. 
Gross margin pressure persists. Analysts blamed under-absorption and pricing actions taken to defend or gain market share. The pricing issues are more strategic and less broad-based than feared.
Automotive was down 26% Q/Q and 25% Y/Y and will likely be down in the high single digits in the second quarter. Auto demand remains dynamic and is not anticipated to materially improve in the next couple of quarters, but Williams noted that the transition to 800V architecture will continue to drive meaningful content expansion and grow penetration, particularly in China.
Industrial fell 4% Q/Q (-16% Y/Y) and is expected to return to growth in second-quarter. Medical and traditional Industrial have improved with signs of stabilization and a few green shoots. 
Pockets of weakness remain, including energy infrastructure. Williams estimates renewable energy makes up &lt; 10% of total revenue, with strong secular tailwinds underpinning healthy growth opportunities, especially as demand recovers.   
Williams projected second-quarter revenue of $1.45 billion and adjusted EPS of 53 cents.
Rosenblatt: ON Semiconductor&#8217;s geographically diversified supply chain should help minimize tariff impacts. 
Adjusted gross margins declined Q/Q and will likely decrease further in the second quarter. The analyst expects a decline in utilization and low single-digit price declines. There continue to be some green shoots (i.e., ON Semiconductor&#8217;s unique Treo Platform, data center power traction, and 200mm SiC). 
Despite some early signs of stabilization in the industrial market, Cassidy noted gross margin pressure overshadowing any positives in the near term.
Cassidy projected second-quarter revenue of $1.45 billion and adjusted EPS of 53 cents.
Needham: ON Semiconductor posted a solid quarter and guide, but gross margin estimates moved lower due to unfavorable pricing and under-absorption charges.
Gross margin will remain under pressure through calendar 2025 as management gets competitive on pricing to defend and gain share in key markets. To offset this, the company is reducing manufacturing capacity by 12% and its workforce by 9%. 
This footprint change removes excess capacity, specifically around the ~$500 million in non-core business (high volume, low mix) the company has walked away from thus far. These structural changes will enable a sharper gross margin improvement when demand returns: for every point of utilization, ON Semiconductor will now see a 25-30bps margin improvement (up from 20-25bps last quarter).
Industrial is stabilizing as bookings picked up towards the end of the first quarter 2025, along with growth in the A&amp;D and Medical end markets. Additionally, the company&#8217;s Consumer Industrial subsegment continues to improve, while Traditional Industrial has been demonstrating nascent signs of recovery.
Most of the headwinds in the Industrial segment seem to be in the rearview mirror. Bolton projected second-quarter revenue of $1.45 billion and adjusted EPS of 53 cents.
Price Action:&nbsp;ON stock is up 0.29% at $38.52 at&nbsp;the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45150491/qualcomm-stock-drops-after-analysts-lower-price-targets-despite-strong-demand-from-apple-and-samsung" target="_blank" rel="noreferrer noopener">Qualcomm Stock Drops After Analysts Lower Price Targets, Despite Strong Demand from Apple and Samsung</a></li>
</ul>
Image: Shutterstock

News

Price Target

Reiteration

Analyst Ratings

Trading Ideas

ON Semiconductor Powers Through Expectations, But Analysts Dial Down Targets On Margin Squeeze

Bristow Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTOL#NYSE">VTOL</a>) reported quarterly earnings of $0.92 per share which beat the analyst consensus estimate of $0.56 by 64.29 percent. This is a 300 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $350.53 million which missed the analyst consensus estimate of $353.00 million by 0.70 percent. This is a 3.99 percent increase over sales of $337.09 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

VTOL

Bristow Group Q1 EPS $0.92 Beats $0.56 Estimate, Sales $350.53M Miss $353.00M Estimate

Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>) affirms FY2025 sales outlook from $535.00 million-$565.00 million to $535.00 million-$565.00 million vs $540.58 million estimate.

Guidance

SWIM

Latham Group Affirms FY2025 Sales Guidance of $535.00M-$565.00M vs $540.58M Est

Golden Heaven Group Holdings Ltd. ("Golden Heaven" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>), an amusement park operator in&nbsp;China, today announced that the Company's board of directors approved on April 23, 2025 that the authorized, issued, and outstanding shares of the Company be consolidated on a 25 for 1 ratio with the marketplace effective date of May 9, 2025.
The objective of the share consolidation is to enable the Company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on Nasdaq.
Beginning with the opening of trading on May 9, 2025, the Company's Class A ordinary shares will trade on the Nasdaq Capital Market on a split-adjusted basis, under the same symbol "GDHG" but under a new CUSIP Number, G3959D208.
As a result of the share consolidation, each 25 ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. No fractional shares will be issued to any shareholders in connection with the share consolidation, and each shareholder will be entitled to receive one share of the Company in lieu of the fractional share of that class that would have resulted from the share consolidation.
At the time the share consolidation is effective, the Company's authorized share capital will be changed from US$200,600,000 divided into: (i) 40,000,000,000 Class A ordinary shares of par value of US$0.005 each, and (ii) 120,000,000 Class B ordinary shares of par value of US$0.005 each, to US$200,600,000 divided into: (i) 1,600,000,000 Class A ordinary shares with a par value of US$0.125 each, and (ii) 4,800,000 Class B ordinary shares with a par value of US$0.125 each. The Company's total issued and outstanding Class A ordinary shares will be changed from 74,323,604 Class A ordinary shares with a par value of US$0.005 each to approximately 2,972,944 Class A ordinary shares with a par value of US$0.125 each. The Company's total issued and outstanding Class B ordinary shares will be changed from 1,840,000 Class B ordinary shares with a par value of US$0.005 each to approximately 73,600 Class B ordinary shares with a par value of US$0.125 each.

GDHG

Golden Heaven Board Approves 25-for-1 Stock Consolidation Effective May 9, 2025

Sandstorm Gold (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAND#NYSE">SAND</a>) reported quarterly earnings of $0.04 per share which met the analyst consensus estimate. This is a 500 percent increase over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $50.06 million which beat the analyst consensus estimate of $49.03 million by 2.10 percent. This is a 16.94 percent increase over sales of $42.81 million the same period last year.

SAND

Sandstorm Gold Q1 EPS $0.04, Inline, Sales $50.06M Beat $49.03M Estimate

Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) raises FY2025 sales outlook from $5.83 billion-$6.03 billion to $5.85 billion-$6.03 billion vs $5.93 billion estimate.

Agilon Health Raises FY2025 Sales Guidance from $5.83B-$6.03B to $5.85B-$6.03B vs $5.93B Est

Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) sees Q2 sales of $1.435 billion-$1.505 billion vs $1.48 billion analyst estimate.

Agilon Health Sees Q2 Sales $1.435B-$1.505B vs $1.48B Est

California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) reported quarterly earnings of $1.07 per share which beat the analyst consensus estimate of $0.78 by 37.18 percent. This is a 42.67 percent increase over earnings of $0.75 per share from the same period last year. The company reported quarterly sales of $912.00 million which beat the analyst consensus estimate of $861.21 million by 5.90 percent. This is a 100.88 percent increase over sales of $454.00 million the same period last year.

California Resources Q1 Adj. EPS $1.07 Beats $0.78 Estimate, Sales $912.00M Beat $861.21M Estimate

Denali Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.68) by 14.71 percent. This is a 14.71 percent decrease over losses of $(0.68) per share from the same period last year.

DNLI

Denali Therapeutics Q1 EPS $(0.78) Misses $(0.68) Estimate

W&amp;T Offshore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTI#NYSE">WTI</a>) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.15) by 40 percent. This is a 320 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $129.87 million which beat the analyst consensus estimate of $123.91 million by 4.81 percent. This is a 7.76 percent decrease over sales of $140.79 million the same period last year.

W&T Offshore Q1 EPS $(0.21) Misses $(0.15) Estimate, Sales $129.87M Beat $123.91M Estimate

Qualys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QLYS#NASDAQ">QLYS</a>) is looking for Q2 Adj EPS of $1.40-$1.50 vs $1.43 analyst estimate. sees sales of $159.700 million-$162.700 million vs $160.01 million analyst estimate.

QLYS

Qualys Sees Q2 Adj EPS $1.40-$1.50 vs $1.43 Est; Sees Sales $159.700M-$162.700M vs $160.01M Est

Unitil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTL#NYSE">UTL</a>) reported quarterly earnings of $1.69 per share which missed the analyst consensus estimate of $1.71 by 1.17 percent. This is unchanged from the same period last year. The company reported quarterly sales of $170.80 million which missed the analyst consensus estimate of $193.03 million by 11.52 percent. This is a 4.42 percent decrease over sales of $178.70 million the same period last year.

Unitil Q1 EPS $1.69 Misses $1.71 Estimate, Sales $170.80M Miss $193.03M Estimate

Lyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYRA#NASDAQ">LYRA</a>) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 62.86 percent increase over losses of $(0.35) per share from the same period last year. The company reported quarterly sales of $183.00 thousand which missed the analyst consensus estimate of $240.00 thousand by 23.75 percent. This is a 65.60 percent decrease over sales of $532.00 thousand the same period last year.

LYRA

Lyra Therapeutics Q1 EPS $(0.13) Beats $(0.15) Estimate, Sales $183.00K Miss $240.00K Estimate

Aris Water Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARIS#NYSE">ARIS</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.29 by 20.69 percent. This is a 2.94 percent increase over earnings of $0.34 per share from the same period last year. The company reported quarterly sales of $120.49 million which beat the analyst consensus estimate of $112.46 million by 7.14 percent. This is a 16.52 percent increase over sales of $103.41 million the same period last year.

ARIS

Aris Water Solutions Q1 Adj. EPS $0.35 Beats $0.29 Estimate, Sales $120.49M Beat $112.46M Estimate

Agilon Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) reported quarterly sales of $1.53 billion which beat the analyst consensus estimate of $1.50 billion by 1.92 percent. This is a 4.44 percent decrease over sales of $1.60 billion the same period last year.

Agilon Health Q1 Sales $1.53B Beat $1.50B Estimate

Stock Split

XChange TEC.INC Announces Plan To Implement ADS Ratio Change From 1 ADS Representing 120 Class A Shares To 1 ADS Representing 2,400 Class A Ordinary Shares

CRSP

CRISPR Therapeutics Q1 EPS $(1.58) Misses $(1.21) Estimate, Sales $865.00K

Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) released its first-quarter results after Tuesday's closing bell. Here's a look at the key figures <a href="https://www.benzinga.com/pressreleases/25/05/b45235079/upstart-announces-results-for-first-quarter-2025">from the quarter.</a>
The Details: Upstart reported quarterly earnings of 30 cents per share, which beat the analyst consensus estimate of 17 cents. Quarterly revenue came in at $213.37 million, which beat the consensus estimate of $199.49 million and is up from revenue of $127.79 million from the same period last year.
Read Next:&nbsp; <a href="https://www.benzinga.com/news/legal/25/05/45226604/president-trump-wants-to-reopen-alcatraz-heres-what-it-would-take?utm_source=articleShare">President Trump Wants To Reopen Alcatraz: Here&#8217;s What It Would Take</a>
Upstart reported transaction volume of 240,706 loans originated, up 102% year-over-year, reflecting a 19.1% conversion rate. Total originations exceeded $2.1 billion, up 89% year-over-year.
&#8220;With an unparalleled pace of innovation, we continue to raise the bar in AI-enabled lending,&#8221; said Dave Girouard, CEO of Upstart. &#8220;In this foundational aspect of our economy, AI is clearly living up to its promise of delivering a radically better product for consumers.&#8221;
Outlook:&nbsp;For the second quarter of 2025, Upstart expects revenue of approximately $225 million and revenue from fees of approximately $210 million. For full-year 2025, Upstart now expects revenue of approximately $1.01 billion and revenue from fees of approximately $920 million. 
The company will host a conference call to discuss the results on Wednesday at 11:30 a.m. ET. 
UPST Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Upstart stock was down 15.95% after-hours at $43.20 on Tuesday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45228179/upwork-delivers-solid-start-to-2025-analyst?utm_source=articleShare">Upwork Delivers &#8216;Solid Start To 2025&#8217;: Analyst&nbsp;</a></li>
</ul>
Photo: Shutterstock

Fintech news covering the emerging Financial Technology services sector

Fintech

After-Hours Center

Movers

UPST

Upstart Stock Drops After Q1 Results: Details

<a href="https://www.globenewswire.com/Tracker?data=ac8FbG8Cp_mK0uZG6iPrMAx5djulUrekP-fOeBOydXp4UMv9PxhXqPmsWO2ZH8F2wMHlBM9v9cZsy2a46haotw==">Cerence Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) ("Cerence AI"), a global leader pioneering conversational AI-powered user experiences, today announced the filing of a copyright infringement and breach of contract lawsuit against Microsoft and Nuance Communications in the United States District Court for the District of Delaware.
Cerence AI and its predecessors have an extensive history of industry-leading innovation and technological achievement. This has resulted in a strong intellectual property portfolio, which the company intends to protect through strategic, continued IP protection efforts. The lawsuit is specific to Cerence AI's text-to-speech technology, a foundational component of the company's product portfolio and its work with both automakers and transportation OEMs, as well as outside of automotive.
"At Cerence AI, we are deeply committed to having our intellectual property rights respected and enforced, especially as we continue to expand to new markets beyond automotive," said Jennifer Salinas, Chief Administrative Officer &amp; General Counsel, Cerence AI. "We believe in the strength of our intellectual property portfolio and plan to vigorously defend our intellectual property rights against infringers. This action against Microsoft and Nuance is necessary to protect our investments, as well as our deep history and culture of innovation."

Legal

CRNC

MSFT

Cerence AI Announces It Has Filed Copyright Infringement Suit Against Microsoft And Nuance

eXp World Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPI#NASDAQ">EXPI</a>) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.01) by 600 percent. This is a 250 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $954.91 million which missed the analyst consensus estimate of $994.83 million by 4.01 percent. This is a 1.26 percent increase over sales of $943.05 million the same period last year.

EXPI

eXp World Holdings Q1 Adj. EPS $(0.07) Misses $(0.01) Estimate, Sales $954.91M Miss $994.83M Estimate

Health Care

Press Releases

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Power Nickel's (TSX.V: PNPN) Hole Delivers "BIG"- Gold Terra (TSX.V: YGT) Developments and Exploration Progress Reported – More Stocks Inside!

Pasithea Therapeutics to Present at the 2025 CAGLA NeauxCancer Conference

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

KTTA

KTTAW

OGEN

PNPNF

TSXV:PNPN

TSXV:YGT

YGTFF

Alzamend Neuro

Azitra

Biodexa Pharmaceuticals plc - American Depositary Shares

Biodexa Pharmaceuticals

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Hldgs

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dermata Therapeutics, Inc. - Common Stock

Dermata Therapeutics

Ensysce Biosciences

Galecto

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Mustang Bio

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

Oragenics

Palisade Bio

Psyence Biomedical Ltd. - Ordinary Shares

Psyence Biomedical

Plus Therapeutics

Sunshine Biopharma

SILO Pharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

VivoSim Labs

Windtree Therapeutics, Inc. - Common Stock

Comments

Pasithea Therapeutics

Intérêt court

Pasithea Therapeutics (NASDAQ:KTTA) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL